These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38802187)

  • 1. Immunohistochemical staining for cytology-based cervical cancer screening.
    Chang WH; Chou FW; Wang PH
    Taiwan J Obstet Gynecol; 2024 May; 63(3):285-287. PubMed ID: 38802187
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it practical to add the p16/Ki67 immunohistochemical dual staining into liquid-based cytology for cervical cancer screening?
    Li YT; Lee NR; Chang WH
    Taiwan J Obstet Gynecol; 2024 May; 63(3):437-438. PubMed ID: 38802218
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
    Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical glandular cells and risk of cervical cancer.
    Burki TK
    Lancet Oncol; 2016 Mar; 17(3):e96. PubMed ID: 26907188
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative analysis of cervical cytology screening methods and staining protocols for detection rate and accurate interpretation of ASC-H: Data from a high-volume laboratory in Turkey.
    Ozlem A; Umit I
    Diagn Cytopathol; 2015 Nov; 43(11):863-9. PubMed ID: 26173757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the CellDetect® staining technique in diagnosis of human cervical cancer.
    He S; Wang GL; Zhu YY; Wu MH; Ji ZG; Seng J; Ji Y; Zhou JM; Chen L
    Gynecol Oncol; 2014 Feb; 132(2):383-8. PubMed ID: 24361533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of novel folate receptor-mediated staining solution detection (FRD) for CIN2+: A systematic review and meta analysis.
    Li YX; Luo HX; Wang W; Wang Z; Zhao WH; Hao M
    Medicine (Baltimore); 2021 May; 100(20):e26004. PubMed ID: 34011097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of cytological examination of the cervix uteri].
    Widy-Kierska K; Gadomska H; Siwik E
    Nowotwory; 1982; 32(4):209-13. PubMed ID: 6193490
    [No Abstract]   [Full Text] [Related]  

  • 9. [ThinPrep liquid-based cervical cytology: a retrospective analysis of 50,340 cases].
    Ma AG; Li Y; He QZ; Ye JL; Lu HJ
    Zhonghua Bing Li Xue Za Zhi; 2009 Feb; 38(2):127-8. PubMed ID: 19573361
    [No Abstract]   [Full Text] [Related]  

  • 10. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study on the Significance of Folate Receptor-Mediated Staining Solution (FRD) Staining in Screening High Grade Cervical Lesions.
    Xiao S; Xie H; Zhu X; Li X; Yi S; Deng X; Xue M
    Med Sci Monit; 2019 Apr; 25():2792-2801. PubMed ID: 30990212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bethesda System, the pathology of preinvasive lesions, and screening technology. The Bethesda System (TBS) of nomenclature for cervical smears.
    Henry M
    J Natl Cancer Inst Monogr; 1996; (21):13-6. PubMed ID: 9101702
    [No Abstract]   [Full Text] [Related]  

  • 13. Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?
    Austin RM; Onisko A; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):602-606. PubMed ID: 32839150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
    Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The equivocal Pap test: its past, present, and future.
    Selvaggi SM
    Diagn Cytopathol; 2010 Jul; 38(7):471-2. PubMed ID: 19941377
    [No Abstract]   [Full Text] [Related]  

  • 16. Dysplasia and early neoplasia of the uterine cervix. A review.
    Briggs RM
    Obstet Gynecol Surv; 1979 Jan; 34(1):70-99. PubMed ID: 375145
    [No Abstract]   [Full Text] [Related]  

  • 17. Accuracy of the Papanicolaou test in the detection of high-grade cervical lesions.
    Repše-Fokter A
    Int J Gynaecol Obstet; 2011 Jan; 112(1):65-6. PubMed ID: 21056413
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
    Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Shall we continue using the Papanicolaou's numerical classification in gynecological cytology?].
    Cerón Esquivel A; Sereno Coló JA
    Ginecol Obstet Mex; 1979 Aug; 46(274):151-5. PubMed ID: 520856
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.